Zobrazeno 1 - 10
of 393
pro vyhledávání: '"drug response prediction"'
Publikováno v:
Onco, Vol 4, Iss 3, Pp 143-162 (2024)
As precision medicine such as targeted therapy and immunotherapy often have limited accessibility, low response rate, and evolved resistance, it is urgent to develop simple, low-cost, and quick-turnaround personalized diagnostic technologies for drug
Externí odkaz:
https://doaj.org/article/2de7fac8377548099f7b8e31f963a18b
Publikováno v:
BioMedInformatics, Vol 4, Iss 2, Pp 1396-1424 (2024)
Background: Ovarian cancer (OC) is the most lethal gynecological cancer in the United States. Among the different types of OC, serous ovarian cancer (SOC) stands out as the most prevalent. Transcriptomics techniques generate extensive gene expression
Externí odkaz:
https://doaj.org/article/240b1378309247688c56729c1a1cb1e8
Autor:
Weronika E. Borek, Luis Nobre, S. Federico Pedicona, Amy E. Campbell, Josie A. Christopher, Nazrath Nawaz, David N. Perkins, Pedro Moreno-Cardoso, Janet Kelsall, Harriet R. Ferguson, Bela Patel, Paolo Gallipoli, Andrea Arruda, Alex J. Ambinder, Andrew Thompson, Andrew Williamson, Gabriel Ghiaur, Mark D. Minden, John G. Gribben, David J. Britton, Pedro R. Cutillas, Arran D. Dokal
Publikováno v:
EBioMedicine, Vol 108, Iss , Pp 105316- (2024)
Summary: Background: Acute myeloid leukaemia (AML) is a bone marrow malignancy with poor prognosis. One of several treatments for AML is midostaurin combined with intensive chemotherapy (MIC), currently approved for FLT3 mutation-positive (FLT3-MP) A
Externí odkaz:
https://doaj.org/article/c1ed1c39383540cb899802e9a5af0c25
Publikováno v:
BMC Bioinformatics, Vol 25, Iss 1, Pp 1-16 (2024)
Abstract Motivation The prediction of cancer drug response is a challenging subject in modern personalized cancer therapy due to the uncertainty of drug efficacy and the heterogeneity of patients. It has been shown that the characteristics of the dru
Externí odkaz:
https://doaj.org/article/0a70f32d741f45208d06a4932a05972a
Autor:
Javiera Obreque, Luis Vergara-Gómez, Nicolás Venegas, Helga Weber, Gareth I. Owen, Pablo Pérez-Moreno, Pamela Leal, Juan Carlos Roa, Carolina Bizama
Publikováno v:
Biological Research, Vol 56, Iss 1, Pp 1-27 (2023)
Abstract In December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo
Externí odkaz:
https://doaj.org/article/53e2cfa4a35d4a9fae6d1f662c519da0
Autor:
Yingke Yang, Peiluan Li
Publikováno v:
BMC Bioinformatics, Vol 24, Iss 1, Pp 1-16 (2023)
Abstract Background In the field of computational personalized medicine, drug response prediction (DRP) is a critical issue. However, existing studies often characterize drugs as strings, a representation that does not align with the natural descript
Externí odkaz:
https://doaj.org/article/c7ec672c3dd640779da26bfb2b1e6d8b
Publikováno v:
PeerJ Computer Science, Vol 10, p e1903 (2024)
Recent advancements in deep learning (DL) have played a crucial role in aiding experts to develop personalized healthcare services, particularly in drug response prediction (DRP) for cancer patients. The DL’s techniques contribution to this field i
Externí odkaz:
https://doaj.org/article/0ab5db3cda994a92980de509c27a4cd2
Autor:
Sana Munquad, Asim Bikas Das
Publikováno v:
Heliyon, Vol 10, Iss 5, Pp e27190- (2024)
The poor prognosis of glioma patients brought attention to the need for effective therapeutic approaches for precision therapy. Here, we deployed algorithms relying on network medicine and artificial intelligence to design the framework for subtype-s
Externí odkaz:
https://doaj.org/article/6e12d0eea41b44c2a597721922b41e7f
Publikováno v:
Applied Sciences, Vol 14, Iss 13, p 5660 (2024)
Cancer research has increasingly utilized multi-omics analysis in recent decades to obtain biomolecular information from multiple layers, thereby gaining a better understanding of complex biological systems. However, the curse of dimensionality is on
Externí odkaz:
https://doaj.org/article/90ae1058da97476fb2e2c69002bb3a2f
Autor:
Danielle Maeser, Robert F. Gruener, Robert Galvin, Adam Lee, Tomoyuki Koga, Florina-Nicoleta Grigore, Yuta Suzuki, Frank B. Furnari, Clark Chen, R. Stephanie Huang
Publikováno v:
Cancers, Vol 16, Iss 9, p 1723 (2024)
Glioblastoma multiforme (GBM) is the deadliest, most heterogeneous, and most common brain cancer in adults. Not only is there an urgent need to identify efficacious therapeutics, but there is also a great need to pair these therapeutics with biomarke
Externí odkaz:
https://doaj.org/article/387a24d76520471abfd993cbce6ddace